DAM
SVA

DLD Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

DLD Asset Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,000
Closed -$86K – 163
2018
Q1 		$86K Sell
10,000
-3,200
-24% -$26.4K 0.01% 103
2017
Q4 		$104K Sell
13,200
-1,800
-12% -$13.5K 0.01% 79
2017
Q3 		$106K Buy
15,000
+5,000
+50% +$34.1K 0.01% 92
2017
Q2 		$68K Buy
+10,000
New +$54.8K 0.01% 92

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

DLD Asset Management's SVA Position: Q2 2018 in Review

DLD Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q2 2018, closing a stake of 10,000 shares — an estimated $86K sold.

DLD Asset Management first reported a position in SVA in Q2 2017 and held it in 4 quarters. The position peaked at $106K in Q3 2017. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2018.

  • DLD Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q2 2018 after selling out during the quarter.
  • DLD Asset Management sold 10,000 Sinovac Biotech, Ltd shares in Q2 2018, an estimated $86K.
  • DLD Asset Management first reported a position in Sinovac Biotech, Ltd in Q2 2017 and held it in 4 quarters.
  • DLD Asset Management's Sinovac Biotech, Ltd position peaked at $106K in Q3 2017.
  • 29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2018.

Based on DLD Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.